on September 14, 2006
Published online before print September 14, 2006, doi: 10.1161/01.ATV.0000245819.32762.cb
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 6, 2006
Accepted on September 1, 2006
Abdominal Aortic Aneurysm. Pathogenesis and Implications for Management
Jonathan Golledge *;
From the Vascular Biology Unit (J.G., J.M.), School of Medicine, James Cook University, Townsville, Australia; Cardiovascular Research Center (A.D.), Gill Heart Institute, University of Kentucky, Lexington; and the School of Surgery and Pathology (P.N.), University of Western Australia, Fremantle Hospital, Fremantle, Western Australia.
* To whom correspondence should be addressed. E-mail: Jonathan.Golledge{at}jcu.edu.au.
Abstract--Abdominal aortic aneurysm (AAA) affects approximately 5% of elderly men and is responsible for a significant number of deaths in Western Countries. At present surgery by open or endovascular means is the only widely used therapy for this condition. In this review we examine the risk factors, serum, and genetic associations of AAA. Epidemiology studies suggest that smoking cessation and control of cholesterol and blood pressure should reduce the number of patients developing AAA. Natural history studies suggest that smoking cessation should reduce the rate of progression of AAA. Clear level 1 evidence for drug treatments of AAA are presently lacking; however, animal and human in vitro studies suggest that medication targeted at reducing inflammation and proteolysis are most likely to be beneficial, with limited data to support the use of statins, Angiotensin II inhibitors, and macrolides. Work has commenced in understanding which patients, identified by clinical, serum, and genotype, are more at risk of AAA progression and thus should be selected out for aggressive treatment. Well designed large multicenter randomized controlled trials are required to examine the medical treatment of AAA.
This article has been cited by other articles:
 |
|
 |
|
  K. I. Paraskevas, C. D. Liapis, G. Hamilton, and D. P. Mikhailidis Are Statins an Option in the Management of Abdominal Aortic Aneurysms? Vascular and Endovascular Surgery, May 1, 2008; 42(2): 128 - 134. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Wang, E. Lee, W. Song, E. Ricciotti, D. J. Rader, J. A. Lawson, E. Pure, and G. A. FitzGerald Microsomal Prostaglandin E Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin II-Induced Abdominal Aortic Aneurysm Formation Circulation, March 11, 2008; 117(10): 1302 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, M. Karan, C. S. Moran, J. Muller, P. Clancy, A. E. Dear, and P. E. Norman Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions Eur. Heart J., March 1, 2008; 29(5): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuivaniemi, C. D. Platsoucas, and M. D. Tilson III Aortic Aneurysms: An Immune Disease With a Strong Genetic Component Circulation, January 15, 2008; 117(2): 242 - 252. [Full Text] [PDF]
|
|
|
|
|
|
J. Golledge, P. Clancy, K. Jamrozik, and P. E. Norman Obesity, Adipokines, and Abdominal Aortic Aneurysm: Health in Men Study Circulation, November 13, 2007; 116(20): 2275 - 2279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Daugherty and L. A. Cassis Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin converting enzyme inhibitors and aortic rupture: population based case control study. Lancet. 2006;368:659-665 Perspectives in Vascular Surgery and Endovascular Therapy, September 1, 2007; 19(3): 342 - 344. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|